-
Mashup Score: 0IFX-dyyb Boosts Rheumatoid Arthritis Outcomes in 6 Months - 5 day(s) ago
A new study provides insight into the effectiveness of IFX-dyyb in a real-world US population of RA patients, showing how the biosimilar compares to other treatments.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Denosumab Biosimilar CT-P41 Demonstrates Pharmacokinetic Equivalence - 1 month(s) ago
The primary endpoint was achieved, with biosimilar CT-P41 demonstrating comparable pharmacokinetics.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Clinical equivalence was demonstrated for the primary and key secondary endpoints between patients receiving MSB11456 and its reference drug, tocilizumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Etanercept, Adalimumab Biosimilars Demonstrate Similar Safety Profile to Originators - 3 month(s) ago
Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Etanercept, Adalimumab Biosimilars Demonstrate Similar Safety Profile to Originators - 3 month(s) ago
Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 10Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand - 4 month(s) ago
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.“While patients are frequently changed from bio-originators to biosimilars, patients’ experiences with the transitioning process are not well
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Study Compares Postoperative Thrombosis Incidence for Branded, Biosimilar Enoxaparin - 5 month(s) ago
There was no statistically significant difference in postoperative thromboembolic events and incident heparin-induced thrombocytopenia among patients treated with branded versus biosimilar enoxaparin.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9
Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
The #biosimilar IFX-dyyb brings notable improvements in disease activity and patient-reported outcomes observed over 6 months, a new study found. https://t.co/WEOyqFdnFe